Investigating genetic characteristics of hepatitis B virus-associated and -non-associated hepatocellular carcinoma

XI-HUA FU 1, MIN LI 2, HAI-BO LOU 1, MING-SHOU HUANG 1 AND CHUN-LONG LIU 3*

1 Department of Infectious Disease, Panyu District Central Hospital, Guangzhou 510000, China
2 Clinical Medicine College of Acupuncture and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou 510000, China
3 Department of Rehabilitation, Clinical Medicine College of Acupuncture and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou 510000, China

(Received 6 April 2016; revised 10 August 2016; accepted 15 August 2016)

Summary

Background: Hepatocellular carcinoma (HCC) is a primary liver malignancy that mainly occurs in patients with chronic liver disease and cirrhosis. Risk factors for HCC include hepatitis B virus (HBV) infection. However, the specific role of HBV infection in HCC development is not yet completely understood. In order to reveal the effects of HBV on HCC, we compare the genes of HCC patients infected with HBV with those who are not infected.

Methods: We encoded the genes of these two types of HCC in databases using enrichment scores of Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway terms. A random forest algorithm was employed in order to distinguish these two types in the classifier, and a series of feature selection approaches was used in order to select their optimal features. Novel HBV-associated and -non-associated HCC genes were predicted, respectively, based on their optimal features in the classifier. A shortest-path algorithm was also employed in order to find all of the shortest-paths genes connecting the known related genes.

Results: A total of 54 different features between HBV-associated and -non-associated HCC genes were identified. In total, 1236 and 881 novel related genes were predicted for HBV-associated and -non-associated HCC, respectively. By integrating the predicted genes and shortest path genes in their gene interaction network, we identified 679 common genes involved in the two types of HCC.

Conclusion: We identified the significantly different genetic features between two types of HCC. We also predicted related genes for the two types based on their specific features. Finally, we determined the common genes and features that were involved in both of these two types of HCC.

1. Introduction

Hepatocellular carcinoma (HCC) is a primary liver malignancy that mainly occurs in patients with chronic liver disease and cirrhosis. HCC is the fifth-leading cause of cancer worldwide, which affected the health of half a million people (Raza & Sood, 2014). From 2002 to 2012, approximately 20,000 new cases were diagnosed in the United States per year. The high incidence of HCC remains a significant threat to public health (Arzumanyan et al., 2013). Since people below the age of 40 seldom get HCC, the likelihood of HCC reaches its peak at approximately 70 years of age (El-Serag, 2011). The incidence of HCC among men is two- to four-times higher than among women (El-Serag, 2011).

The pathogenic mechanism of HCC is complicated, with many of risk factors, mainly including alcoholic fatty liver disease, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and hereditary hemochromatosis (Lin et al., 2012). The lower-risk factors include autoimmune hepatitis, porphyrias, α1-antitrypsin deficiency and Wilson’s disease. However, these risk factors are unevenly distributed across the world depending on racial background, geographic region and environmental factors (El-Serag & Rudolph, 2007). Worldwide, chronic HBV infection is a major
underlying cause of HCC, accounting for approximately 50% of all HCC cases (El-Serag, 2012). Case-control studies have shown that the incidence of HCC in chronic HBV carriers was 5–15 times greater than that of people without chronic HBV infection, which is particularly applicable to endemic regions such as Asia and Africa. In these areas, HBV is usually transmitted by vertical transmission (from mother to fetus). The high prevalence of HBV strongly contributes to the development of HCC and chronic liver disease (El-Serag & Rudolph, 2007). In areas with low HCC incidence rates, HBV is mainly spread in adulthood by horizontal transmission (sexual and parenteral routes). More than 90% of acute HBV infections recover spontaneously (El-Serag, 2012). Both HBV and other aetiological factors are likely to induce chronic liver diseases, such as liver cirrhosis, which is the most common aetiology of hepatic carcinoma (Floyd, 1962).

The prognosis of HCC is one of the worst in cancer, as it is usually detected in its late stages (Feitelson, 2006). Understand the underlying molecular mechanisms and identifying its potential gene targets will be useful for early detection and clinical therapies (Lambert et al., 2011).

Many efforts have been made to reveal the underlying pathogenetic mechanism of HCC. However, the specific role of HBV in HCC development is not yet completely understood, and the difference between HBV-associated HCC (hereafter referred to as HBVαHCC) and HBV-non-associated HCC (hereafter referred to as HBVνHCC) is still not clear. Here, we explore an integrated method based on Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, which have been widely used to annotate enrichment, to analyse the function of genes (Rhodes & Chinnaiyan, 2005) and to explore the underlying mechanisms of HBVαHCC and HBVνHCC. Shortest path algorithm was employed to find all shortest paths connecting any two of the known HBVαHCC or HBVνHCC related genes. Genes that occurred in at least one shortest path were regarded as candidates (Floyd, 1962). Further analysis indicated that some candidate genes had been previously reported as HCC-related genes based on literature searches. We hope that our results help to uncover the mechanism of HCC and provide new insights for early diagnosis and novel therapies.

2. Methods

2.1. Encoding genes for classification and prediction

GO (Shaw et al., 1999) is a major bioinformatics initiative aimed at standardizing the description of gene functions and gene products that will facilitate computer-driven information retrieval and the generation of new knowledge from omics-scale data. The KEGG database (Hsieh et al., 2004) is high-quality database covering a collection of manually drawn pathway maps representing our knowledge of the molecular interactions and reaction networks of metabolism, genetic information processing, environmental information processing, cellular processes, human diseases and drug development. Gene properties can be depicted by using GO and KEGG pathway annotation. If two genes share a similar function, they will have similar annotations in GO and KEGG pathways. Therefore, we encoded each gene as a numeric vector consisting of an enrichment score for each of the GO and KEGG terms. The GO or KEGG enrichment score is defined as its $–\log_{10}$ of the $p$-value for examining hyper-geometric tests for one gene or its interaction neighbours (Carmona-Saez et al., 2007; Yang et al., 2014) in a Search Tool for Recurring Instances of Neighbouring Genes (STRING) network. A higher enrichment score means a higher degree of enrichment. As a result, a gene is encoded as an eigenvector with 6242 GO terms and 214 KEGG pathways.

2.2. Selecting optimal features from positive and negative samples

A series of feature selection methods was adopted, such as minimum redundancy maximum relevance (mRMR) (Peng et al., 2005), incremental feature selection (IFS) (Peng et al., 2005) and a random forest (RF) algorithm (Ge & Zhang, 2014; Mao et al., 2014).

Specifically, the mRMR method is based on the maximum relativity and minimum redundancy for sorting the features to be screened. Then, IFS was applied in order to make the processing accord with the order that mRMR returns. Once each additional feature is added, classifications were performed in order to evaluate the results of these known features. A classifier is used together with the RF algorithm (using Weka3-6-4 [Bouckaert et al., 2010] in the RF algorithm). In classification evaluation, ten-fold cross-validation was used in order to simultaneously calculate the true-positive (TP) rate, the true-negative (TN) rate, the false-positive (FP) rate and the false-negative (FN) rate. Then, Matthews’s correlation coefficient (MCC) based on the TP, TN, FP and FN rates was used in order to summarize the performance of the classification. When the maximum MCC first appeared, the combination of the features was regarded as the optimal feature set, and they were the maximum relevance and minimum redundancy features of osteoarthritis-related genes. The MCC value was calculated by:

$$
MCC = \frac{TP \times TN - FP \times FN}{\sqrt{(TP + FP) (TP + FN) (TN + FP) (TN + FN)}}
$$

X.-H. Fu et al.
2.3. Predicting novel candidate genes related to HBVaHCC and HBVnHCC

The optimal features of HBVaHCC and HBVnHCC were selected and employed in the RF classifier in order to predict related genes. All of the annotated genes in the Ensemble database were also encoded by GO and KEGG and used as the test samples. The known HBVaHCC- or HBVnHCC-related genes were used as the training samples, respectively. The RF classifier was used in order to predict novel HBVaHCC and HBVnHCC genes, respectively.

2.4. Identifying the shortest-path genes based on a STRING network

Previous studies (Deng et al., 2003; Ng et al., 2010; Hu et al., 2011; Mathews et al., 2011) have indicated that genes that could interact with each other share similar functions. Thus, we constructed a network based on the gene–gene interactions from STRING (Jensen et al., 2009). Each interaction in STRING was evaluated with the standard of interaction confidence score ranging from 1 to 999 in order to measure the likelihood of interaction. Dijkstra’s algorithm was applied to the R package ‘igraph’ so as to identify the shortest path between each gene pair. In order to find all of the shortest paths connecting any two genes, we selected the genes that occurred in at least one shortest path as candidate genes through applying the shortest-path algorithm to this network. Then, a randomization test was employed in order to filter these candidate genes.

2.5. HCC specimens and quantitative real-time RT-PCR

Thirty HCC tumour tissues and 20 matched adjacent normal liver tissues were obtained from surgical resection at Panyu District Central Hospital (Guangzhou, China). Routine in situ hybridization for HBV-encoded RNA was performed in order to classify HBVaHCC or HBVnHCC. There were 14 HBVaHCC tissues and 16 HBVnHCC tissues in our tumour tissues. Total RNA was extracted from the snap-frozen tumour tissues or adjacent normal liver tissues with TRIzol reagent (Life Technology). cDNA was obtained by reverse transcription of RNA. Quantitative RT-PCR was performed on an ABI 7900 HT Sequence Detection System (Applied Biosystems) using TaqMan Gene Expression Master Mix (4369016, Applied Biosystems). The expression values were shown as relative expression levels to GAPDH. The primer sequences are shown in Supplementary Table 1 (available online).

2.6. Ethics statement

Prior written informed consent was obtained from each patient, and the study was conducted in accordance with the principles of the Declaration of Helsinki and approved by Panyu District Central Hospital.

3. Results

3.1. Known HBVaHCC- or HBVnHCC-related genes in databases

The Genetic Association Database (Zhang & Lu, 2015) is a comprehensive database of complex human diseases that includes the disease genes of complex diseases annotated by the reported literature and genome-wide association study experimental data. When searching the database with “hepatitis B hepatocellular carcinoma” as the keyword, we obtained 52 HBVaHCC-related genes. Moreover, by searching with “hepatocellular carcinoma” as the keyword and removing the HBV-associated genes, we obtained 129 HBVnHCC-related genes.

The DisGeNET Database (Sun & Karin, 2008) annotates disease genes through the integration of public databases and gene–disease relationships in the reported literature. Currently, the database contains 381,056 gene–disease relationships (covering 16,666 genes and 13,172 kinds of disease). When searching the database with “hepatitis B virus-related hepatocellular carcinoma” (umls: C1333977) as the keyword, we obtained 16 genes. In the same way, we found the HBVnHCC-related genes from the DisGeNET and Catalogue of Somatic Mutations in Cancer (COSMIC) (Forbes et al., 2011) databases.

We found a total of 63 HBVaHCC-related genes and 152 HBVnHCC-related genes (no duplicates) through database searches, whose specific gene names and database sources are shown in Supplementary Table 2.

3.2. Optimal features for distinguishing HBVaHCC-related and HBVnHCC-related genes

The HBVaHCC-related and HBVnHCC-related genes collected from the databases were encoded by GO and KEGG. In order to identify the features that could describe the differences between HBVaHCC and HBVnHCC, we took HBVaHCC genes as the positive samples and HBVnHCC genes as the negative samples. We employed a series of feature selection procedures in order to identify the optimal features that could distinguish these samples. As a result, these optimal features between these two types of HCC were different, containing 52 GO terms and two KEGG terms (as shown in Table 1).

The GO terms consist of three main types: the biological process, the cellular component and the molecular function GO terms. In order to exemplify the profile of the huge GO terms in the optimal set, we grouped them into the children of three root GO
terms (as shown in Fig. 1). The children terms briefly described the different GO terms for distinguishing HBVaHCC-related and HBVnHCC-related genes. The KEGG terms are pathways of “O mannosyl glycan biosynthesis” and “melanogenesis”.

3.3. Optimal feature sets for distinguishing tumour-related genes in HBVaHCC and HBVnHCC

We also compared HBVaHCC-related genes with other genes and HBVnHCC-related genes with other genes in Table 1.

| Rank | Term ID   | Term name                                               |
|------|-----------|---------------------------------------------------------|
| 1    | GO:0006869| Lipid transport                                        |
| 2    | GO:0090002| Establishment of protein localization to plasma membrane|
| 3    | GO:0031410| Negative regulation of the Toll-like receptor 3 signalling pathway |
| 4    | GO:0007588| Excretion                                              |
| 5    | GO:0021541| Ammon gyrus development                                 |
| 6    | GO:0017121| Phospholipid scrambling                                 |
| 7    | GO:0008170| N-methyltransferase activity                            |
| 8    | GO:0019099| Leukocyte-mediated cytotoxicity                         |
| 9    | GO:0055585| Collagen type II                                        |
| 10   | GO:006117 | Acetaldehyde metabolic process                          |
| 11   | GO:006606 | Protein import into nucleus                             |
| 12   | GO:0070401| NADP + binding                                         |
| 13   | GO:0047844| Deoxycytidine deaminase activity                        |
| 14   | GO:016011 | Dystroglycan complex                                    |
| 15   | GO:006629 | Lipid metabolic process                                 |
| 16   | GO:038061 | NIK/NF-κB signalling                                    |
| 17   | GO:0072091| Regulation of stem cell proliferation                   |
| 18   | GO:005643 | Nuclear pore                                            |
| 19   | GO:0097062| Dendritic spine maintenance                             |
| 20   | KEGG:O_Mannosyl_glycan_biosynthesis                    |
| 21   | GO:0004047| Aminomethyltransferase activity                         |
| 22   | GO:0032039| Integrator complex                                      |
| 23   | GO:005664 | Nuclear origin of replication recognition complex       |
| 24   | GO:0016638| Oxidoreductase activity, acting on the CH–NH₂ group of donors |
| 25   | GO:001773 | Myeloid dendritic cell activation                       |
| 26   | GO:0048619| Embryonic hindgut morphogenesis                         |
| 27   | GO:190011 | Negative regulation of corticotropin-releasing hormone receptor activity |
| 28   | GO:000715 | Nucleotide excision repair, DNA damage recognition      |
| 29   | GO:000586 | U2 snRNP                                                |
| 30   | GO:0034361| Very-low-density lipoprotein particle                   |
| 31   | GO:0035048| Acetylcholine receptor regulator activity               |
| 32   | GO:0045263| Proton-transporting ATP synthase complex, coupling factor F(0) |
| 33   | GO:0017145| Stem cell division                                      |
| 34   | GO:0034136| Negative regulation of the Toll-like receptor 2 signalling pathway |
| 35   | GO:1902203| Negative regulation of the hepatocyte growth factor receptor signalling pathway |
| 36   | GO:0061003| Positive regulation of dendritic spine morphogenesis    |
| 37   | GO:0036414| Histone citrullination                                  |
| 38   | GO:0005762| Mitochondrial large ribosomal subunit                   |
| 39   | GO:0015886| Haem transport                                          |
| 40   | GO:0016884| Carbon–nitrogen ligase activity, with glutamine as amido-N-donor |
| 41   | KEGG:Melanogenesis                                   |
| 42   | GO:0030897| HOPS complex                                            |
| 43   | GO:0035641| Locomotory exploration behaviour                        |
| 44   | GO:0031665| Negative regulation of the lipopolysaccharide-mediated signalling pathway |
| 45   | GO:0030728| Ovulation                                               |
| 46   | GO:0008066| Glutamate receptor activity                             |
| 47   | GO:002839 | Positive regulation of immune response to tumour cells  |
| 48   | GO:005102 | Heparan sulphate proteoglycan biosynthetic process      |
| 49   | GO:0060330| Regulation of response to interferon-γ                  |
| 50   | GO:2001113| Negative regulation of the cellular response to hepatocyte growth factor stimulus |
| 51   | GO:000445 | THO complex, part of the transcription export complex   |
| 52   | GO:006741 | Prostate gland stromal morphogenesis                    |
| 53   | GO:001502 | Haem–copper terminal oxidase activity                   |
| 54   | GO:0032021| NELF complex                                            |
order to investigate the characteristics of HBVaHCC- and HBVnHCC-related genes. The tumour genes were taken as the positive samples and other genes were randomly selected as the negative samples. Specifically, HBVaHCC had 63 tumour-related genes as positive samples and 252 other genes randomly selected as negative samples. HBVnHCC had 152 tumour-related genes as positive samples and 508 other genes randomly selected as negative samples. Because the number of negative samples was much larger than that of the positive samples, the negative samples were randomly divided into four groups. The four negative sample sets and their corresponding positive samples were formed as four training sets, HBVaHCC and HBVnHCC respectively. The feature selecting classifier identified the optimal features in the four HBVaHCC and four HBVnHCC training sets, respectively. The corresponding number of features was considered to be the optimal feature set in the eight groups when the MCC value reached the maximum. Finally, we took the union of four optimal feature sets in HBVaHCC and HBVnHCC as the final optimal feature set of HBVaHCC and HBVnHCC, respectively.

Therefore, the optimal features for predicting HBVaHCC-related genes included 1768 GO terms and 70 KEGG pathways (as shown in Supplementary Table 3), while the optimal features for predicting HBVnHCC included 1202 GO terms and 59 KEGG pathways (as shown in Supplementary Table 4). The feature terms of the two types of HCC were different for the most part, which was coherent with the distinct mechanism of cancer development. It was demonstrated that we could adopt these features in order to distinguish these two types of HCC.

3.4. Novel HBVaHCC and HBVnHCC genes predicted by optimal GO and KEGG pathway terms

Based on the above optimal features of HBVaHCC and HBVnHCC genes, we predicted novel related
Table 2. The 69 overlaps between the predicted genes and the genes obtained from shortest-path analysis

| CFTR  | TSC2  | CCNB1 | PARP1 | IRS1 |
|-------|-------|-------|-------|------|
| CREBBP| TGBF1 | GSTM1 | EGER  | HDAC3|
| CD4   | AHR   | IL6ST | IGFBP3| BCL2 |
| FYN   | TGBF1 | MDM2  | IL18  | RELA |
| BRCA1 | MAP3K | IL6   | PSMD4 | JUN  |
| IGFI  | CCND1 | RIPK1 | SHC1  | GRB2 |
| HSP90AA1| IL23A | CASP1 | JAK1  | PTPN11|
| ESRI  | GAPDH | RB1   | IL23R | LCK  |
| JAK2  | HADC1 | IGF1R | CDC25A| SP1  |
| MAPK1 | PIK3CA| CYPIA1| CASP3 | PTPN1|
| EP300 | PLG   | TP53  | SYK   | SRC  |
| HIF1A | CDK2  | ERBB2 | CTNNB1| MAP3K5|
| YY1   | CDKN1A| AKTI  | STAT3 | UGT1A8|
| NFKBIA| RAI1  | ARNT  | MAP2K1|

genes from all of the annotated genes. The RF algorithm acted as the prediction machine in order to help us determine the genes that had similar functions to the known HBVaHCC- and HBVnHCC-related genes. We predicted 1290 genes as being related to HBVaHCC and 1005 genes related to HBVnHCC (as shown in Supplementary Table 5). Among them, 1236 and 881 genes were novel genes, respectively.

3.5. Shared genes related to both HBVaHCC and HBVnHCC

In the genes that were predicted by the classifier, there were 639 shared genes between HBVaHCC and HBVnHCC (as shown in Supplementary Table 6), accounting for approximately 50% of the total number of predicted genes. As these two types were both related to HCC development, it was expected that they would share most of their genes. We also employed another approach, the shortest-path analysis, in order to determine the HBVaHCC-related and HBVnHCC-related genes in the gene interaction network and collect the shared genes. We consequently obtained the candidate related genes and determined the betweenness of them. In the shortest-path network, the betweenness of genes indicates the number of shortest paths containing the gene as an inner node and connecting all pairs. Therefore, it is possible that genes with higher betweenness were more likely to have been related to cancer genes than those with lower betweenness. Through the shortest-path analysis, we identified the related genes and found 108 shared genes for both types (as shown in Supplementary Table 7). In total, there were 679 shared genes as found by combining the predicted genes through the classifier and shortest-path genes. In addition, there were 69 overlaps between the predicted genes and the genes obtained from the shortest-path analysis (as shown in Table 2). These genes were considered to have similar functions to the known related genes and, indeed, they interacted with these known related genes, which was worthy of further investigation.

3.6. Expression verification of the identified genes in tumour and normal tissues

In order to confirm the presence of these overlapped genes in HCC specimen, we compared the expression of the top ten relevant genes for both HBVaHCC and HBVnHCC between tumour tissues and normal tissues by quantitative real-time RT-PCR. We verified six significantly up-regulated genes and two significantly down-regulated genes in HBVaHCC tissues (Fig. 2(a)) and verified seven significantly up-regulated genes and one significantly down-regulated gene in HBVnHCC tissues (Fig. 2(b)). These genes have similar expression patterns in the two types of HCC. CASP3, HDAC1, IRS1, RAF1, RIPK1 and SYK were significantly up-regulated in both HBVaHCC and HBVnHCC tissues. FYN was significantly down-regulated in both tissues. This result suggested that our system of biological measurement for identifying HCC-related genes was reliable.

4. Discussion

4.1. Different features of HBVaHCC and HBVnHCC

As a unique kind of hepatocellular cancer, HBVaHCC is triggered by HBV and has some distinct features. Based on GO and KEGG enrichment analysis, we obtained 54 GO and KEGG features in the optimal feature list (as shown in Table 1), which included 31 biological process terms, 12 cellular component terms, nine molecular function terms and two KEGG terms. Some GO terms were shown to be highly related to the differences between HBVaHCC and HBVnHCC. For example, inclusion of GO:0002839 (positive regulation of the immune response to tumour cell), GO:0005303 (regulation of response to interferon-γ) and GO:0001909 (leukocyte-mediated cytotoxicity) revealed that the immune antiviral response to the HBV proteins played an important role in HBVaHCC (Chen et al., 2005).

GO:0034136 (negative regulation of the Toll-like receptor 2 [TLR2] signalling pathway) and GO:0038061 (NIK/NF-κB signalling) might contribute to distinguishing HBVaHCC from HBVnHCC. NF-κB transcription factors and Toll-like receptors are crucial regulators of danger recognition and immune responses. Activation of the TLR3 pathway plays an important role in suppressing HBV replication in the liver, and TLR ligands might act as the promising therapeutics for chronic HBV infections (Zhang & Lu, 2015). The NF-κB pathway has great relevance to several liver diseases, including chronic HBV infection, fibrosis, liver cirrhosis and HCC, and has an important hepatoprotective function. The NF-κB pathway might serve as
a useful target for the treatment of HCC (Sun & Karin, 2008).

GO:0016638 (oxidoreductase activity, acting on the \(\text{CH}–\text{NH}_2\) group of donors) and GO:0015002 (haem–copper terminal oxidase activity) has been associated with oxidative reactions, and the pre-S mutant of HBsAg has been reported to contribute to the oxidative stress and DNA damage of hepatocytes (Hsieh et al., 2004).

GO:0005585 (collagen type II) refers to the process by which type II collagen triply forms \(\text{fi}\)brils and is highly associated with HBVaHCC. It has been reported that HBV infection may have an indirect effect on the occurrence of HCC through the fibrosis process (Mantych et al., 1991). Hepatocellular fibrosis will induce architecture derangement and portal hypertension. The irreversible rearrangement of the \(\text{fi}\)brils may cause cirrhosis (Chu & Liaw, 2006).

Some terms, including GO:0006117 (acetaldehyde metabolic process), GO:0047844 (deoxycytidine deaminase activity), GO:0016011 (dystroglycan complex), GO:0015012 (heparan sulphate proteoglycan biosynthetic process), GO:0045263 (proton-transporting ATP synthase complex), coupling factor F(o) and ‘KEGG: O mannosyl glycan biosynthesis’ are believed to be involved in metabolism and cellular biosynthesis. Compared with normal tissues, tumours have many important alterations in metabolic pathways supporting the rapid growth and proliferation of cancer cells by providing rapid ATP generation and increasing the biosynthesis of macromolecules. It is clear that genetic mutations and the tumour microenvironment can alter cellular metabolism (Cairns et al., 2011). It is known that various tumours caused by different molecular mechanisms may have many common but unique alterations and metabolic profiles (Baenke et al., 2013). The inclusion of these terms indicates that HBVaHCC and HBVnHCC may have some distinct underlying features of metabolism.

GO:0072091 (regulation of stem cell proliferation) and GO:0017145 (stem cell division) refer to the process by which stem cells proliferate and divide in order to provide cells that can develop into mature and functional cells. These terms are associated with cell growth and proliferation, which are common hallmarks of cancer and may play an important role in HCC (Xiao et al., 2004).

4.2. Analysis of the optimal features characterizing HBVaHCC-related genes

We selected the top 15 GO children terms ranked by relevance to HBVaHCC for further analysis. They covered 12 biological process terms, one cellular component term and two molecular function GO terms. Several GO terms were shown to be highly related to HBVaHCC. HBVaHCC had several shared but distinctive characteristics compared with HBVnHCC. GO:0009636 (response to toxic substances), GO:0032870 (cellular response to hormone stimuli) and GO:0034059 (response to anoxia) were all related to the cellular stress response to stimuli. It is known that HBV can infect liver cells and activate several important reactions that can contribute to the development of HCCs. For example, the HBV X protein (HBx) has pleiotropic effects, including cell responses to genotoxic stress, cell division and apoptosis (Zhang et al., 2006).
The inclusion of GO:0010884 (positive regulation of lipid storage) and GO:0010957 (negative regulation of the vitamin D biosynthetic process) met our expectations. As we discuss in Section 4.1, there is increasing evidence supporting the implications of metabolism in hepatocellular cancer development (Montella et al., 2011; Jump et al., 2015).

The inclusion of GO:0097200 (cysteine-type endopeptidase activity involved in the execution phase of apoptosis) implied that cell apoptosis was associated with HBVaHCC. HBx is a key regulator of HBV replication that plays an important role in the development of HBVaHCC (Ha & Yu, 2010). HBx modulates a variety of cellular pathways, including apoptosis. Thus, deregulation of normal apoptotic pathways might influence the development and progress of HCC (Rawat et al., 2012).

The inclusion of GO:0006999 (nuclear pore organization), GO:0030118 (clathrin) and GO:0045837 (negative regulation of membrane potential) in the top feature list might provide us with new insights for understanding the mechanisms of HBVaHCC.

4.3. Analysis of the optimal features characterizing HBVnHCC-related genes

We chose the top 15 features associated with HBVnHCC for further analysis. The top 15 feature list contained 11 biological process terms, two molecular function terms and two cellular component terms. Some GO terms were related to HBVnHCC.

GO:0038186 (lithocholic acid receptor activity) was also highly related to the development of cancer. Lithocholic acid was effective at killing several types of cancer cells, including some brain tumours and breast cancers. It is reported that lithocholic acid specifically targeted cancer cells without killing normal cells, which might improve existing chemotherapy drugs (Arlia-Ciommio et al., 2014). Findings have shown that lithocholic acid has a broad anti-tumour effect on several kinds of cancer cells derived from different tissues (Goldberg et al., 2011).

GO:0070664 (negative regulation of leukocyte proliferation) refers to any process that reduces or prevents the extent of leukocyte proliferation, which is highly related to hepatocellular cancer. HCC is a typical kind of inflammation-related cancer. Several studies have indicated that the tumour microenvironment and leukocyte infiltrate play important roles in the development and progress of inflammation-related cancers by secreting cytokines, chemokines and growth factors (Capece et al., 2013). Immune responses participate in different stages of cancer, such as tumour initiation, malignant conversion and metastasis. It has been generally accepted that inflammation plays an essential role in tumorigenesis; therefore, an inflammatory microenvironment is required for all kind of tumours (Grivennikov et al., 2010).

GO:0097057 (TRAF2–GSTP1 complex) was involved in disrupting TNF signalling and regulating inflammatory responses. Monocytes and many other immunological cells secrete TNF cytokines, which have been implicated in tumorigenesis (Balkwill, 2006). By binding to receptors, TNF could activate various downstream signalling cascades, including inflammatory, apoptotic and stress pathways, such as the NF-κB, MAPK and JNK pathways in tumours (Roderburg et al., 2012).

GO:0001541 (ovarian follicle development) and GO:0001542 (ovulation from ovarian follicles) were associated with the progression of the ovarian follicle. Ovaries might be related to HCC. It has been reported that a small fraction of HCCs can spread to the ovaries (de Groot et al., 2000; Papp et al., 2003).

4.4. Shared genes related to both HBVaHCC and HBVnHCC

Although HBVaHCC and HBVnHCC differ greatly in many aspects, they also have a lot of characteristics in common. Previous research has demonstrated that all kinds of cancers share several common features, including cell growth, proliferation, apoptosis and metastasis, which contribute to the malignant transformation of normal cells. Based on the analysis of the shortest-path algorithm, we found a number of genes that might be associated with HBVaHCC and HBVnHCC, several of which were subsequently confirmed by experimental data from previously published research.

The protein encoded by the BAD gene belongs to the BCL-2 family, which is known for module cell apoptosis. Phosphorylated BAD protein has been reported to be down-regulated in HCC cells compared with normal hepatocytes. The loss of phosphorylated BAD results in deregulation of cell apoptosis, which might play a key role in liver tumourigenesis (Yoo et al., 2006). The CD38 gene encodes a multifunctional ectoenzyme that is widely expressed in different tissues, especially in leukocytes. The CD38 molecule is strongly associated with cancer development and has been reported to be up-regulated on the cell surfaces of leukemic B cells (Bauvois et al., 1999). The protein encoded by CREBBP is a transcriptional co-activator and important regulator of eukaryotic gene expression. It is involved in the transcriptional regulation of many important transcription factors, including P53 (Grossman, 2001). Dysfunction of this gene probably contributes to cancer development (Mullighan et al., 2011). The PROM1 gene encodes a transmembrane glycoprotein located on membrane protrusions. It has been reported to be involved in suppressing cell differentiation and maintaining stem cell properties. PROM1 is known to be highly related to HCC and...
HBV and non-associated HCC

has often served as a marker of hepatoblast and liver cancer stem cells (Katoh & Katoh, 2007; Andrisani et al., 2011).

The NOS2 gene is also associated with HCC. The protein encoded by NOS2 is a nitric oxide synthase expressed in liver. As a reactive free radical, nitric oxide participates in several processes, including anti-microbial and anti-cancer pathways (Levesque et al., 2001). The levels of nitric oxide in HCC are significantly down-regulated compared with adjacent non-tumour liver tissues ($p < 0.001$). Compared with adjacent normal liver tissues, the expression levels of NOS2 and nitric oxide in HCC are significantly down-regulated in HCC. These decreased levels of nitric oxide/NOS2 might contribute to HCC development and progression (Zhou et al., 2012).

Note that the HBVnHCC-related genes constitute the HCC-related gene set that was not associated with HBV in order to cater to our design. Therefore, the HBVnHCC genes used here could include genes that are involved in other causes of HCC, and the HBVnHCC genes in this study constituted a complex group. HCV infection is another main risk factors for HBVnHCC genes in this study constituted a complex that are involved in other causes of HCC, and the HBVnHCC genes used here could include genes other synonyms in the databases. There were only 19 genes that were related to HCV in the HBVnHCC genes. Removing these 19 genes, we again analysed the remaining 133 HBVnHCC genes. The optimal features for distinguishing the new HBVnHCC genes from the other genes constituted 1097 terms, 164 fewer than that of the previous HBVnHCC group. These 164 optimal features included 159 GO terms and five KEGG terms. The significant differences of these optimal features compared with the previous ones were the absence of terms for antioxidant activity, receptor regulator activity, protein binding transcription factor activity, extracellular regions and cell junctions. Using the new optimal features, the 209 genes that had been previously predicted to be HBVnHCC-related genes now were predicted to be non-related ones.

In this study, we collected the known HBVaHCC- or HBVnHCC-related genes from public databases and analysed their genetic features. Comparing the features between two types of HCC, we identified 52 GO terms and two KEGG terms for distinguishing them. Comparing the features of HBVaHCC- or HBVnHCC-related genes to the features of genes with no relation to HCC, we identified the optimal features for extracting HBVaHCC- and HBVnHCC-related genes and predicted 1236 and 881 novel genes for them, respectively. We further analysed the gene interaction network and also found some genes that might be involved in HCC by using the shortest-path algorithm. Combing the predicted genes through classifier and shortest-path genes, we identified 679 shared genes for the two types of HCC. These findings might provide genetic targets for studying the roles of HBV in HCC, as well as useful insights for understanding the pathogenesis of HCC with or without HBV.

This work was supported by Guangdong Province Science and Technology Planning Project (No. 20130319C) and Guangzhou University of Chinese Medicine Pass-it-on Project (No. XH20140117).

5. Declaration of interest

None.

6. Supplementary material

For supplementary material accompanying this paper visit https://doi.org/10.1017/S0016672316000124.

References

Andrisani, O. M., Studach, L. & Merle, P. (2011). Gene signatures in hepatocellular carcinoma (HCC). Seminars in Cancer Biology 21, 4–9.
Arlia-Ciommio, A., Piano, A., Svistkova, V., Mohtashami, S. & Titorenko, V. I. (2014). Mechanisms underlying the anti-aging and anti-tumor effects of lithocholic bile acid. International Journal of Molecular Science 15, 16522–16543.
Arzumanyan, A., Reis, H. M. & Feitelson, M. A. (2013). Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nature Reviews Cancer 13, 123–135.
Bensen, F., Peck, B., Niess, H. & Schulze, A. (2013). Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Disease Models & Mechanisms 6, 1353–1363.
Balkwill, F. (2006). TNF-alpha in promotion and progression of cancer. Cancer Metastasis Review 25, 409–416.
Bauvois, B., Durant, L., Laboureau, J., Barthelemy, E., Rouillard, D., Boulla, G., et al. (1999). Upregulation of CD38 gene expression in leukemic B cells by interferon types I and II. Journal of Interferon & Cytokine Research 19, 1059–1066.
Bouckaert, R. R., Frank, E., Hall, M. A., Holmes, G., Pfahringer, B., Reutemann, P., et al. (2010). WEKA – experiences with a Java open-source project. The Journal of Machine Learning Research 11, 2533–2541.
Cairns, R. A., Harris, I. S. & Mak, T. W. (2011). Regulation of cancer cell metabolism. Nature Reviews Cancer 11, 85–95.
Capece, D., Fischietti, M., Verzella, D., Gaggiano, A., Cicciarelli, G., Tessitore, A., et al. (2013). The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. BioMed Research International 2013, 187204.
Carmo-Reis, P., Chagoyen, M., Tirado, F., Carazo, J. M. & Pascual-Montano, A. (2007). GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists. Genome Biology 8, R3.
Chen, Y., Wei, H., Sun, R. & Tian, Z. (2005). Impaired function of hepatic natural killer cells from murine chronic HBsAg carriers. International Immunopharmacology 5, 1839–1852.
Chu, C. M. & Liaw, Y. F. (2006). Hepatitis B virus-related cirrhosis: natural history and treatment. Semininars in Liver Disease 26, 142–152.
de Groot, M. E., Dukel, L., Chadha-Ajwani, S., Metselaar, H. J., Tilanus, H. W. & Huikeshoven, F. J. (2000). Massive solitary metastasis of hepatocellular carcinoma in the ovary two years after liver transplantation. *European Journal of Obstetrics, Gynecology, and Reproductive Biology* **90**, 109–111.

Deng, M., Zhang, K., Mehta, S., Chen, T. & Sun, F. (2003). Prediction of protein function using protein–protein interaction data. *Journal of Computational Biology* **10**, 947–960.

El-Serag, H. B. (2011). Hepatocellular carcinoma. *New England Journal of Medicine* **365**, 1118–1127.

El-Serag, H. B. (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology* **142**, 1264–1273.e1.

El-Serag, H. B. & Rudolph, K. L. (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* **132**, 2557–2576.

Feitelson, M. A. (2006). Parallel epigenetic and genetic changes in the pathogenesis of hepatitis virus-associated hepatocellular carcinoma. *Cancer Letters* **239**, 10–20.

Floyd, R. W. (1962). Algorithm 97: shortest path. *Communications of the ACM* **5**, 345.

Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., et al. (2011). COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. *Nucleic Acids Research* **39**, D945–D950.

Ge, H., Zhang, G. (2010). RETRACTED: identifying halophilic proteins based on random forests with preprocessing of the pseudo-amino acid composition. *Journal of Theoretical Biology* **361**, 175–181.

Goldberg, A. A., Beach, A., Davies, G. F., Harkness, T. A., Leblanc, A. & Titoenton, V. I. (2011). Lithocholic bile acid selectively kills neuroblastoma cells, while sparing normal neuronal cells. *Onco target* **2**, 761–782.

Grivennikov, S. I., Greten, F. R. & Karin, M. (2010). Immunity, inflammation, and cancer. *Cell* **140**, 883–899.

Grossman, S. R. (2001). p300/CBP/p53 interaction and *p* value. *Mathews, L. A., Cabarecs, S. M., Hurt, E. M., Zhang, X., Jaffee, E. M. & Farrar, W. L. (2011). Increased expression of DNA repair genes in invasive human pancreatic cancer cells. *PloS One* **9**, e104049.

Hu, L., Huang, T., Liu, X. J. & Cai, Y. D. (2011). Predicting protein function correlation based on mutual information: criteria of max-dependency, max-relevance, and min-redundancy. *IEEE Transactions on Pattern Analysis and Machine Intelligence* **37**, 1226–1238.

Hu, H. L. & Yu, D. Y. (2010). HBV-induced reactive oxygen species activates hepatocellular carcinogenesis via dysregulation of PTEN/Akt pathway. *World Journal of Gastroenterology* **16**, 4932–4937.

Hsieh, Y. H., Su, I. J., Wang, H. C., Chang, W. W., Lei, H. Y., Lai, M. D., et al. (2004). Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. *Carcinogenesis* **25**, 2023–2032.

Hu, L., Huang, T., Liu, X. J. & Cai, Y. D. (2011). Predicting protein functional interactions based on protein–protein interaction network. *PLoS One* **6**, e17668.

Jensen, L. J., Kuhn, M., Stark, M., Chaffron, S., Creevey, C., Muller, J., et al. (2009). STRING 8 – a global view on proteins and their functional interactions in 630 organisms. *Nucleic Acids Research* **37**, D412–D416.

Jump, D. B., Depner, C. M., Tripathy, S. & Lytle, K. A. (2015). Potential for dietary omega-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer. *Advances in Nutrition* **6**, 694–702.

Katoh, Y. & Katoh, M. (2007). Comparative genomics on the human genome. *BMC Evolutionary Biology* **7**, 412–426.

Lebesque, M. C., Hobbs, M. R., Anstey, N. M., Chancellor, J. A., Misukonis, M. A., Granger, D. L., et al. (2001). A review of polymorphisms in the human gene for inducible nitric oxide synthase (NOS2) in patients with malaria. *Sepsis* **4**, 217–231.

Lin, S., Hoffmann, K. & Schmmer, P. (2012). Treatment of hepatocellular carcinoma: a systematic review. *Liver Cancer* **1**, 144–158.

Mantych, G., Devaskar, U., deMello, D. & Devaskar, S. (1991). GLUT 1-glucose transporter protein in adult and fetal mouse lung. *Biochemical and Biophysical Research Communications* **180**, 367–373.

Mao, R., Raj Kumar, P. K., Guo, C., Zhang, Y. & Liang, C. (2014). Comparative analyses between retained introns and constitutively spliced introns in Arabidopsis thaliana using random forest and support vector machine. *PLoS One* **9**, e104049.

Mathews, L. A., Cabarcas, S. M., Hurt, E. M., Zhang, X., Jaffee, E. M. & Farrar, W. L. (2011). Increased expression of DNA repair genes in invasive human pancreatic cancer cells. *PloS One* **9**, e104049.

Ng, K. L., Ciou, J. S. & Huang, C. H. (2010). Prediction of protein functions based on function–function correlation relations. *Computers in Biology and Medicine* **40**, 300–305.

Papp, B., Pal, C. & Hurst, L. D. (2003). Dosage sensitivity and the evolution of gene families in yeast. *Nature* **424**, 194–197.

Peng, H., Long, F. & Ding, C. (2005). Feature selection based on mutual information: criteria of max-dependency, max-relevance, and min-redundancy. *IEEE Transactions on Pattern Analysis and Machine Intelligence* **27**, 1226–1238.

Rawat, S., Clippinger, A. J. & Bouchard, M. J. (2012). Modulation of apoptotic signaling by the hepatitis B virus X protein. *Viruses* **4**, 2945–2972.

Raza, A. & Sood, G. K. (2014). Hepatocellular carcinoma review: current treatment, and evidence-based medicine. *World Journal of Gastroenterology* **20**, 4115–4127.

Rhodes, D. R. & Chinnaiyan, A. M. (2005). Integrative analysis of the cancer transcriptome. *Nat Genet Suppl., 37*, A419–A419.

Roderburg, C., Gautheron, J. & Luedde, T. (2012). TNF-dependent signaling pathways in liver cancer: promising targets for therapeutic strategies? *Digestive Disease* **30**, 500–507.

Shaw, D. R., Ashburner, M., Blake, J. A., Baldarelli, R. M., Botstein, D., Davis, A. P., et al. (1999). Gene Ontology: a controlled vocabulary to describe the function, biological process and cellular location of gene products in genome databases. *American Journal of Human Genetics* **65**, A419–A419.

Sun, B. & Karin, M. (2008). NF-kappaB signaling, liver disease and hepatoprotective agents. *Onco gene* **27**, 6228–6244.

Xiao, E. H., Li, J. Q. & Huang, J. F. (2004). Effects of p53 on apoptosis and proliferation of hepatocellular carcinoma cells treated with transcatheter arterial chemotherapy. *World Journal of Gastroenterology* **10**, 190–194.

Yang, J., Chen, L., Kong, X., Huang, T. & Cai, Y. D. (2014). Analysis of tumor suppressor genes based on gene ontology and the KEGG pathway. *PLoS One* **9**, e107202.
Yoo, N. J., Lee, J. W., Jeong, E. G., Soung, Y. H., Nam, S. W., Lee, J. Y., et al. (2006). Expressional analysis of anti-apoptotic phospho-BAD protein and mutational analysis of pro-apoptotic BAD gene in hepatocellular carcinomas. *Digestive and Liver Disease* **38**, 683–687.

Zhang, E. & Lu, M. (2015). Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. *Medical Microbiology and Immunology* **204**, 11–20.

Zhang, X., Zhang, H. & Ye, L. (2006). Effects of hepatitis B virus X protein on the development of liver cancer. *The Journal of Laboratory and Clinical Medicine* **147**, 58–66.

Zhou, L., Wang, Y., Tian, D. A., Yang, J. & Yang, Y. Z. (2012). Decreased levels of nitric oxide production and nitric oxide synthase-2 expression are associated with the development and metastasis of hepatocellular carcinoma. *Molecular Medicine Reports* **6**, 1261–1266.